

1 **SENATE FLOOR VERSION**

2 March 2, 2022

3 **AS AMENDED**

4 SENATE BILL NO. 1467

5 By: David

6 **[state Medicaid program - Oklahoma Health Care**
7 **Authority to conduct certain annual review -**
8 **publication of annual report - codification -**
9 **effective date]**

10 BE IT ENACTED BY THE PEOPLE OF THE STATE OF OKLAHOMA:

11 SECTION 1. NEW LAW A new section of law to be codified
12 in the Oklahoma Statutes as Section 5026.1 of Title 63, unless there
13 is created a duplication in numbering, reads as follows:

14 A. The Oklahoma Health Care Authority shall conduct an annual
15 review of all medications and forms of treatment for sickle cell
16 disease and services for enrollees with a diagnosis of sickle cell
17 disease. The purpose of the annual review is to determine if the
18 available covered medications, treatments, and services are adequate
19 to meet the needs of enrollees with a diagnosis of sickle cell
20 disease, and whether the Authority should seek to add or recommend
21 additional medications, treatments, or services.

22 B. The review shall include, but not be limited to:

23 1. The extent to which healthcare transitional programs covered
24 under the state Medicaid program prepare, transfer, and integrate

1 emerging adults into the adult care setting from a pediatric
2 setting;

3 2. The extent to which emergency department providers are
4 adequately trained and otherwise prepared to treat and manage sickle
5 cell patients presenting with vaso-occlusive crises including but
6 not limited to the extent to which providers follow clinically
7 validated algorithms and protocols regarding such treatment and
8 management;

9 3. The extent to which sickle cell patients covered under the
10 state Medicaid program are entitled to receive the same standard of
11 care when referred or transferred to an out-of-state facility, and
12 the extent to which the state reimburses such patients for
13 reasonable interstate travel costs; and

14 4. Any additional areas identified by the Authority that impact
15 the care and treatment of individuals in this state living with
16 sickle cell disease or sickle cell trait.

17 C. When conducting the annual review required by this section,
18 the Authority shall solicit and consider input from the general
19 public, with specific emphasis on seeking input from persons or
20 groups with knowledge and experience in the area of sickle cell
21 disease treatment.

22 D. To the extent practicable, the Authority shall utilize the
23 Oklahoma State Health Information Network and Exchange created under
24

1 Section 1-133 of Title 63 of the Oklahoma Statutes to collect
2 information for the purpose of implementing this section.

3 E. On or before January 15, 2023, and on or before January 15
4 each year thereafter, the Authority shall submit a report to the
5 President Pro Tempore of the Senate and the Speaker of the House of
6 Representatives for distribution to the appropriate subject matter
7 committees that details the Authority's findings from the annual
8 review required by this section and any recommendations to the
9 Legislature based upon those findings. The Authority shall publish
10 the annual report required by this subsection to its website in a
11 manner accessible by the general public.

12 SECTION 2. This act shall become effective November 1, 2022.

13 COMMITTEE REPORT BY: COMMITTEE ON APPROPRIATIONS
14 March 2, 2022 - DO PASS AS AMENDED

15
16
17
18
19
20
21
22
23
24